WE ARE EARLY PHASETRIAL EXPERTISETHERAPEUTIC EXPERTISE We are EARLY Phase We do one thing only, and we do it reliably in all shapes and colours – even yours. FIND OUT WHO WE ARE Trial Expertise We deliver reliable research on everything first-in-human. And we do it in every relevant field and in our own clinical facilities. LEARN ABOUT OUR METHODOLOGIES Therapeutic EXPERTISE Our specialised units in 5 locations handle indications that range from cardiovascular to respiratory. SEE OUR EXPERTISE BY INDICATION A Thorough QT Study of Teduglutide in Healthy Subjects.SciencePharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment.ScienceOnce-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.ScienceSequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.Science read more in our blog Studies in cooperation with: REACHING OUT IS EASY AND FAST – LET’S TALK Prof. Dr. Thomas Forst Chief Medical Officer (CMO) located at CRS Mannheim LET’S TALK SCIENCE firstname.lastname@example.org+49 621 150 45 – 0 Dr. Volker Menschik Chief Business Officer (CBO)located at CRS Berlin LET’S TALK BUSINESS email@example.com+49 30 859 949 – 0 CRO Leadership Awards 2019 CRS is proud to be recognised again by pharma companies worldwide as a leading CRO with regard to: capabilities, compatibility, quality and reliability. European Biotechnology Guide Find CRS’s company profile in the European Biotechnology Science Industry Guide, volume 9 2019. EcoVadis – CSR Rating Based on the CSR rating by EcoVadis in July 2018 CRS has been granted Silver Recognition Level.